Tumor necrosis factor alpha (TNF-α) inhibitors, such as the monoclonal antibody infliximab, have also been used to treat refractory sarcoidosis [20], including some cases of cardiac sarcoidosis, however, infliximab use in patients with heart failure has been associated with a dose-dependent increased risk of heart failure-related death [21]. Here, TNF is linked to cardiac sarcoidosis.